| has gloss | eng: BEACOPP is a chemotherapy regimen for treatment of Hodgkins lymphoma in Stages > II developed by the . Patients typically receive treatment in cycles of 21 days with no drugs given on days 16-21. There also exists a more intensive regimen with cycles of 14 days. Usually a therapy consists of eight, sometimes six cycles. In some countries BEACOPP still is experimental, in others (e.g. Germany and Austria) it is a standard therapy. In the United States, ABVD (or Stanford V) is generally given instead, because BEACOPP is thought to induce more secondary neoplasias (such as leukemias) . This has not been proven after 10 years of experience in other countries. Some consider that the BEACOPP regimen is not generally given for cost reasons; it is indeed more expensive as it requires G-CSF support. However, BEACOPP delivers approximately 10-15% more cures in advanced Hodgkins disease (IIB+risk factors or stages III and IV). |